

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 6, 2017**

**Synergy Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**001-35268**  
(Commission  
File Number)

**33-0505269**  
IRS Employer  
Identification No.)

**420 Lexington Avenue, Suite 2012**  
**New York, NY 10170**  
(Address of principal executive offices)

Registrant's telephone number, including area code: **(212) 297-0020**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 8.01 Other Events.**

On September 6, 2017, Synergy Pharmaceuticals Inc. (the "Company") issued a press release announcing that the company will present corporate updates at three upcoming investment conferences in New York City during September. The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 [Synergy Pharmaceuticals Inc. Press Release dated September 6, 2017.](#)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 6, 2017

SYNERGY PHARMACEUTICALS INC.

By: /s/ Gary S. Jacob

Gary S. Jacob, Ph.D.

President and Chief Executive Officer

## Synergy Pharmaceuticals to Present at Upcoming September Investment Conferences

**NEW YORK, September 6, 2017** — Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present corporate updates at three upcoming investment conferences in New York City during September:

Rodman & Renshaw 19<sup>th</sup> Annual Global Investment Conference on Monday, September 11, 2017 at 9:35 a.m. Eastern Time.

2017 Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 10:20 a.m. Eastern Time.

Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 10:30 a.m. Eastern Time.

A live webcast of the presentations will be accessible through the Investor Relations section of the company's website at [www.synergypharma.com](http://www.synergypharma.com). A replay of the webcast will be available on Synergy's website for 90 days following each conference.

### About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy's proprietary GI platform includes one commercial product TRULANCE™ (plecanatide) and a second lead product candidate, dolcanatide. For more information, please visit [www.synergypharma.com](http://www.synergypharma.com).

### Company Contact:

Synergy Pharmaceuticals Inc.  
Gem Hopkins, 212-584-7610  
VP, Investor Relations and Corporate Communications  
[ghopkins@synergypharma.com](mailto:ghopkins@synergypharma.com)

---